INMD -5.45 to 22.54, getting crushed even after the recent selloff ..... after the Q2 report the stock was at $44, so down around 50% since late July whereas the annual revenue guidance is down only 6% ..... seems oversold to me, but maybe you're right that investors are seeing this reduced guidance as just the beginning of an extended period of revenue and earnings decline. I'm mulling over adding some shares, but it might be a mistake.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.